Competing interests
F.M. received consultant fees from Novartis and Pegascy. E.D. received personal fees and non-financial support from Novartis, Pfizer, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Eli Lilly and Merck Sharp & Dohme. T.F. received consultant fees outside the submitted work and compensation to the institution from Cellectis, Roche and Eli Lilly. B.P. received fees as advisor/consultant from Pierre Fabre (self), Daiichi Sankyo (self), Merck Sharp & Dohme (institution), Seattle Genetics (institution), Eli Lilly (institution) and Novartis (institution); funding to institution for research support from Daiichi Sankyo and AstraZeneca; and travel expenses from AstraZeneca, Pfizer and Gilead. T.B. reports receiving grants and personal fees from Daiichi Sankyo, AstraZeneca, Pfizer and Seattle Genetics and personal fees from Novartis and Roche outside the submitted work. M.K. and T.K. are employees of Daiichi Sankyo RD Novare. M.L.T. received consultant fees as speaker and consultant from AstraZeneca and Daiichi Sankyo. V.D. received travel expenses from Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Daiichi Sankyo, Seagen and Gilead; honoraria as consultant/advisor from Roche, Genentech, Novartis, Eli Lilly, Pfizer, AstraZeneca, AbbVie, Merck Sharp & Dohme, Daiichi Sankyo, Seagen, Gilead, Eisai and Pierre Fabre Oncologie; and honoraria for symposia from Roche, Novartis, Pfizer, Eli Lilly, Astra Zeneca, Daiichi Sankyo, Seagen and Gilead. F.A. received research funding and served as speaker/advisor (compensated to the hospital) from Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Eli Lilly. The following authors have no disclosures: A.L., L.L.B., Y.P., A.D., F.V., C.L., N.S., A.A., D.T.N.T., I.J.G., H.T., S.C., M.V., N.D., A.S., L.L., P.S., J.B., M.D., M.J., C.M., V.B., P.L., P.K. and V.M.